POZ - ICAAC : ICAAC: MK-0518 Appears Lipid Friendly - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
POZ Focus

Back to home » Newsfeed » Conference Coverage » ICAAC

Table of Contents

Diary of a Doc: Vaccine Update at ICAAC

ICAAC: Trizivir vs. Reyataz/Combivir

ICAAC: Norvir-Boosted Lexiva vs. Reyataz

Predictive Value of Viral Load Testing Questioned

ICAAC: MK-0518 Potent for Treatment Experienced

ICAAC: More Drug-Resistant HIV?

ICAAC: Prezista and Aptivus on Drug-Resistant HIV

Prezista Women's Study Opens for Enrollment

ICAAC Opens in San Francisco

ICAAC: Predicting Responses to Aptivus or Prezista

ICAAC: MK-0518 Appears Lipid Friendly

ICAAC: Abortion Pill for HIV? Questions Still Remain

What You're Talking About
Let's Kick ASS - AIDS Survivor Syndrome (32 comments)

It's Time for a TV Dramedy Series About Life With HIV (27 comments)

AHF Campaigns Against PrEP as a 'Public Health Intervention' (25 comments)

True Story - An essay by a gay journalist and author who is tired of living in fear of HIV (17 comments)

Depression, God and Staying Alive... (blog) (17 comments)

Health Care is a Human Right (8 comments)
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


ICAAC: MK-0518 Appears Lipid Friendly

by Tim Horn

September 27, 2006 (AIDSmeds)—New data suggest that MK-0518 does not cause increased cholesterol or triglyceride as a side effect of treatment. The "late breaker" report, highlighting preliminary results from a study comparing Merck's experimental integrase inhibitor MK-0518 to Bristol-Myers Squibb's non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva® (efavirenz), was presented on Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

Emerging clinical trial results indicate that MK-0518, when combined with other HIV medications, will likely be a potent addition to the current therapeutic armamentarium. Twenty-four week study data presented at the XVI International AIDS Conference, held in Toronto in August (and to be reported again at ICAAC), suggest that MK-0518 holds a great deal of promise for people with drug-resistant HIV in need of new treatment choices. It has also been suggested that this integrase inhibitor may be a useful regimen component for patients with drug-sensitive virus beginning therapy for the first time.

Beyond its effectiveness, HIV-positive people and their healthcare providers have been eager to learn more of MK-0518's side effect profile. Encouragingly, the new data presented at ICAAC indicates that one of the most frequently noted side effects of NNRTIs and most protease inhibitors (PIs) – elevated lipid levels associated with an increased risk of cardiovascular problems – may not be a problem with this compound.

The preliminary 24-week results are from an ongoing 48-week study involving 198 HIV-positive people starting therapy for the first time. The patients were randomized to take either one of four doses of MK-0518 (100mg, 200mg, 400mg, or 600mg twice daily) or Sustiva (600mg once daily). All patients also took Viread® (tenofovir) and Epivir® (lamivudine).

Upon entering the study, the patients in the MK-0518 groups had average total cholesterol levels of 161 to 168 mg/dL. After 24 weeks, total cholesterol decreased by 2 mg/dL to 7 mg/dL in these groups. Among those in the Sustiva group, the average total cholesterol level at study entry was 170 mg/dL. After 24 weeks, their total cholesterol levels increased, on average, by 19 mg/dL. The differences between the MK-0518 groups and the Sustiva group with respect to total cholesterol changes was statistically significant, meaning that the differences weren't due to chance.

As for triglycerides, patients taking MK-0518 had average levels of 110 mg/dL to 155 mg/dL upon entering the study. Twenty-four weeks later, there was a 2 mg/dL increase in the 100mg group and a decrease of 43 mg/dL in the 600mg group. Patients taking Sustiva had an average pre-treatment triglyceride level of 129 mg/dL, which increased 47 mg/dL after 24 weeks of treatment. These differences were also statistically significant.

The complete 48-week study results, including differences between MK-0518 and Sustiva with respect to viral load and CD4 (T4 cell) count changes, will likely be presented early next year.

"This study provides important preliminary data on this investigational compound in regard to lipid parameters in patients with HIV disease," said Hedy Teppler, M.D., director of Infectious Diseases and Clinical Research at Merck. "Longer term follow-up of these patients is planned to confirm these findings."


[ Go to top ]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    New Hope

    New York

Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Are you a regular coffee drinker?

Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.